Castle Biosciences Inc (NAS:CSTL)
$ 24.21 +1.39 (+6.07%) Market Cap: 734.29 Mil Enterprise Value: 509.33 Mil PE Ratio: 0 PB Ratio: 1.59 GF Score: 73/100

Castle Biosciences Inc DecisionDx-Melanoma Call Transcript

Mar 23, 2026 / 08:30PM GMT
Release Date Price: $25.75 (+3.00%)
Operator

Good afternoon, and welcome to Castle Biosciences DecisionDx melanoma webcast. As a reminder, today's webcast is being recorded.

Dr. Guenther and Dr. Goldberg will begin with a presentation that follows the accompanying slide deck, followed by a brief question-and-answer session.

I would now like to turn the call over to Dr. Matthew Goldberg, Senior Vice President of Medical for Castle Biosciences.

Matthew Goldberg
Castle Biosciences Inc - Senior Vice President - Medical

Thank you, operator, and good afternoon, everyone. My name is Matt Goldberg. I'm a board-certified dermatologist, dermatopathologist and I serve as Senior Vice President of Medical here at Castle Biosciences.

Before we get into the publication itself and before Dr. Guenther takes us through the data in detail, I want to spend a few minutes setting the clinical stage for why this study matters. And my goal here is to ground the discussion of the questions physicians are actually trying to answer in early-stage melanoma and then to level set the DecisionDx melanoma

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot